Thioredoxins Inhibitors
3 drugsAbout Thioredoxins
Thioredoxins are ubiquitous proteins functioning as oxidoreductases, critical for redox signaling and maintaining cellular homeostasis. They catalyze disulfide bond formation and reduction, playing a key role in various biological processes.
Currently, there is no genetic evidence directly linking thioredoxins to specific diseases. However, the existence of three FDA-approved drugs suggests therapeutic potential by modulating thioredoxin activity.
Three FDA-approved small molecule drugs (SELENIOUS ACID, MULTRYS, and TRALEMENT) target thioredoxins. These drugs, developed by AM REGENT, are classified within the 'other' therapeutic area.
Top Thioredoxins Drugs
AM REGENT is the only company with approved drugs targeting thioredoxins.
The market's sole player indicates high barriers to entry or a lack of perceived commercial opportunity.
Thioredoxins Drug Modality Landscape
Modalities
Routes of Administration
Thioredoxins is druggable by small molecules, though no oral formulations are currently approved.
The exclusive use of small molecules suggests an opportunity for novel modalities like antibodies or peptides.
Thioredoxins Clinical Trials 45 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Thioredoxins. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 4 | 3 | 1 | 0 | 75% |
| Phase 2 | 15 | 11 | 0 | 4 | 100% |
| Phase 3 | 11 | 9 | 0 | 2 | 100% |
| Phase 4 | 15 | 12 | 2 | 1 | 86% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Thioredoxins Drug Approval Timeline (2020 - 2020)
The approval timeline spans from 2019 (SELENIOUS ACID) to 2020 (TRALEMENT).
The recent approvals suggest renewed interest, but the short timespan may indicate market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 38 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Thioredoxins. A trial counts if an approved drug acting on Thioredoxins is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.